Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Fulgent Genetics	Burning Rock Biotech	Veracyte	Genetron	Castle Biosciences
Symbol	NASDAQ:FLGT	NASDAQ:BNR	NASDAQ:VCYT	NASDAQ:GTH	NASDAQ:CSTL
Price Information
Current Price	$70.02	$26.14	$39.89	$18.11	$54.56
52 Week Range	Hold	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.4	1.1	1.4	0.4	1.9
Analysis Score	1.1	2.5	3.3	1.5	3.5
Community Score	2.4	2.5	3.1	0.6	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.0	0.0	0.0	2.5
Earnings & Valuation Score	2.5	0.6	0.6	0.0	0.6
Analyst Ratings
Consensus Recommendation	Hold	Buy	Buy	Buy	Buy
Consensus Price Target	$74.40	$32.30	$58.43	$19.50	$85.00
% Upside from Price Target	6.26% upside	23.57% upside	46.47% upside	7.68% upside	55.79% upside
Trade Information
Market Cap	$2.03 billion	$2.73 billion	$2.68 billion	$1.61 billion	$1.37 billion
Beta	1.92	N/A	0.77	N/A	0.46
Average Volume	1,840,918	343,180	945,257	399,740	296,100
Sales & Book Value
Annual Revenue	$32.53 million	N/A	$120.37 million	$45.68 million	$51.87 million
Price / Sales	62.40	N/A	22.28	35.23	26.35
Cashflow	$0.14 per share	N/A	N/A	N/A	$0.10 per share
Price / Cash	498.37	N/A	N/A	N/A	539.36
Book Value	$4.42 per share	N/A	$4.90 per share	N/A	$4.98 per share
Price / Book	15.84	N/A	8.14	∞	10.96
Profitability
Net Income	$-410,000.00	N/A	$-12,600,000.00	$-95,470,000.00	$5.28 million
EPS	$0.02	N/A	($0.27)	N/A	($0.81)
Trailing P/E Ratio	34.66	0.00	N/A	0.00	N/A
Forward P/E Ratio	12.97	N/A	N/A	∞	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	35.31%	N/A	-30.46%	N/A	-5.30%
Return on Equity (ROE)	43.81%	N/A	-12.27%	N/A	-2.69%
Return on Assets (ROA)	36.82%	N/A	-10.95%	N/A	-2.05%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	0.07%
Current Ratio	3.39%	9.84%	26.60%	5.74%	6.65%
Quick Ratio	3.39%	9.59%	26.28%	5.68%	6.59%
Ownership Information
Institutional Ownership Percentage	33.39%	15.79%	N/A	19.56%	66.42%
Insider Ownership Percentage	45.00%	N/A	8.30%	N/A	39.70%
Miscellaneous
Employees	480	938	320	799	199
Shares Outstanding	28.99 million	104.55 million	67.24 million	88.87 million	25.06 million
Next Earnings Date	8/3/2021 (Estimated)	5/25/2021 (Confirmed)	7/29/2021 (Estimated)	5/24/2021 (Confirmed)	8/9/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	Castle Biosciences (NASDAQ:CSTL) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS americanbankingnews.com - May 11 at 3:38 PM
	BTIG Stick to Their Buy Rating for Castle Biosciences investing.com - May 11 at 1:42 PM
	Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Buy" by Analysts americanbankingnews.com - May 11 at 10:19 AM
	Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors finance.yahoo.com - May 11 at 8:42 AM
	Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related Conditions businesswire.com - May 11 at 1:52 AM
	Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermat us.acrofan.com - May 10 at 8:51 PM
	Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates finance.yahoo.com - May 10 at 8:51 PM
	Castle Biosciences (NASDAQ:CSTL) Issues FY 2021 Earnings Guidance americanbankingnews.com - May 10 at 4:44 PM
	Castle Biosciences (NASDAQ:CSTL) Shares Gap Down to $60.32 americanbankingnews.com - May 10 at 3:26 PM
	Update: Castle Biosciences (NASDAQ:CSTL) Stock Gained 79% In The Last Year finance.yahoo.com - May 7 at 12:52 PM
	Notable Two Hundred Day Moving Average Cross - CSTL nasdaq.com - May 6 at 4:39 PM
	Castle Biosciences (NASDAQ:CSTL) Earns Buy Rating from Analysts at Lake Street Capital americanbankingnews.com - May 6 at 4:04 PM
	Castle Biosciences (NASDAQ:CSTL) Coverage Initiated by Analysts at Lake Street Capital marketbeat.com - May 6 at 8:50 AM
	New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test finance.yahoo.com - May 5 at 8:39 AM
	Castle Biosciences (NASDAQ:CSTL) Shares Gap Down to $66.71 americanbankingnews.com - May 4 at 11:06 AM
	Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S. finance.yahoo.com - May 4 at 9:44 AM
	Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for finance.yahoo.com - May 3 at 5:37 PM
	Castle Biosciences (CSTL) to Release Quarterly Earnings on Monday americanbankingnews.com - May 3 at 8:18 AM
	Zacks: Analysts Anticipate Castle Biosciences, Inc. (NASDAQ:CSTL) Will Post Quarterly Sales of $17.14 Million americanbankingnews.com - May 2 at 1:02 AM
	Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!" Steps Challenge for Skin Cancer Awareness Month wallstreet-online.de - May 1 at 9:53 AM
	-$0.22 Earnings Per Share Expected for Castle Biosciences, Inc. (NASDAQ:CSTL) This Quarter americanbankingnews.com - April 30 at 8:16 PM
	Lake Street Capital Initiates Coverage on Castle Biosciences (NASDAQ:CSTL) americanbankingnews.com - April 30 at 11:44 AM
	Castle Biosciences (NASDAQ:CSTL) Now Covered by Analysts at Lake Street Capital marketbeat.com - April 30 at 9:57 AM
	Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month finance.yahoo.com - April 30 at 8:35 AM
	Castle Biosciences (NASDAQ:CSTL) Stock Price Down 5.3% americanbankingnews.com - April 28 at 1:59 PM
	Critical Contrast: Castle Biosciences (NASDAQ:CSTL) vs. Exagen (NASDAQ:XGN) americanbankingnews.com - April 27 at 8:16 PM
	Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory finance.yahoo.com - April 27 at 7:47 AM

Date	Company	Brokerage	Action
3/11/2021	Fulgent Genetics	Piper Sandler	Boost Price Target
2/1/2021	Fulgent Genetics	Oppenheimer	Boost Price Target
1/8/2021	Fulgent Genetics	Credit Suisse Group	Downgrade
11/24/2020	Fulgent Genetics	BTIG Research	Downgrade
9/25/2020	Fulgent Genetics	CSFB	Boost Price Target
11/5/2019	Fulgent Genetics	Piper Jaffray Companies	Upgrade
7/13/2020	Burning Rock Biotech	Bank of America	Initiated Coverage
7/7/2020	Burning Rock Biotech	Morgan Stanley	Initiated Coverage
7/7/2020	Burning Rock Biotech	Cowen	Initiated Coverage
5/11/2021	Veracyte	SVB Leerink	Lower Price Target
5/11/2021	Veracyte	Needham & Company LLC	Lower Price Target
1/27/2021	Veracyte	Truist	Initiated Coverage
12/17/2020	Veracyte	Lake Street Capital	Boost Price Target
11/9/2020	Veracyte	KeyCorp	Initiated Coverage
11/2/2020	Veracyte	William Blair	Reiterated Rating
9/30/2020	Genetron	Canaccord Genuity	Reiterated Rating
3/9/2021	Castle Biosciences	Robert W. Baird	Lower Price Target

(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources